Opioid Neurotoxicity and Rotation in Advanced Prostate Cancer With Renal Failure
A 66-year-old man with metastatic castration-resistant prostate cancer and diffuse bone metastases has pain 6/10 despite morphine sulfate extended-release 60 mg PO every 12 hours plus morphine immediate-release 15 mg PO every 2 hours as needed, of which he has used four doses daily for the past two weeks. Over five days he has developed increasing sedation, intermittent myoclonus, and new confusion; his wife says he is 'hard to wake' between doses. Labs: creatinine 2.4 mg/dL (baseline 1.1), estimated CrCl 26 mL/min, calcium 9.1 mg/dL, sodium 134 mmol/L. He takes denosumab, abiraterone, prednisone 5 mg daily, and senna/docusate. He is on no benzodiazepine or gabapentinoid. Pain remains 6/10.
1. What is the most likely explanation for the sedation, myoclonus, and confusion, and what are your first actions?
Read the worked answer
This is opioid neurotoxicity from accumulation of morphine metabolites, not pain progression alone. Morphine-6-glucuronide (analgesic and sedating) and morphine-3-glucuronide (neuroexcitatory) are renally cleared; with CrCl falling to 26 mL/min they accumulate, producing sedation, myoclonus, hyperalgesia, and delirium at doses that were previously tolerated.
First actions:
- Stop morphine - both the extended-release and immediate-release products.
- Do not give a full naloxone reversal. In an opioid-tolerant patient this precipitates severe withdrawal, pain crisis, and seizures. Reserve naloxone for respiratory depression or inability to rouse, given as 0.04 mg IV increments titrated to respiratory rate, not to full alertness.
- Look for and treat contributors: hypercalcemia of malignancy (currently normal at 9.1 but recheck), brain metastases or leptomeningeal disease, urinary retention, infection, dehydration/uremia, and the 5 mg prednisone (can worsen delirium and hyperglycemia).
- Hydrate cautiously and monitor urine output; reassess renal function - if the AKI is reversible, metabolite clearance will improve.
- Do not add a benzodiazepine or antihistamine for the myoclonus; if needed, clonazepam is used sparingly but worsens sedation. Reducing the opioid burden is the treatment.
Document that the confusion predates any new sedative so the etiology stays clear.
2. Perform the opioid rotation. Show your equianalgesic calculation, state any dose reduction, and give a concrete regimen with breakthrough dosing.
Read the worked answer
Step 1 - Current total daily dose: morphine ER 120 mg/day + IR 4 x 15 mg = 60 mg/day -> 180 mg oral morphine/day.
Step 2 - Choose the drug. In renal failure, fentanyl is preferred (hepatic metabolism, inactive metabolites) and methadone is a reasonable expert alternative (no active renal metabolites, but QT monitoring and complex conversion). Hydromorphone is acceptable but its glucuronide metabolites also accumulate, so it must be dosed conservatively.
Step 3 - Convert to fentanyl. Using 25 mcg/h transdermal ~ 60 mg oral morphine/day: 180/60 x 25 = 75 mcg/h. Apply a 25-30% reduction for incomplete cross-tolerance plus his current toxicity -> 50 mcg/h patch every 72 hours (start conservatively at 25 mcg/h if the team judges the neurotoxicity severe; you can always titrate up).
Step 4 - Bridge and breakthrough. The patch takes 12-24 hours to reach effect, so overlap with short-acting analgesia: hydromorphone 1 mg PO every 4 hours as needed (low dose deliberately, given renal impairment) for the first 24-48 hours. Breakthrough should be roughly 10-15% of the total daily dose.
Alternative if pain is unstable: transdermal fentanyl is a poor fit for rapidly titrating pain. In that case start a hydromorphone continuous subcutaneous infusion or scheduled IR dosing, stabilize, then convert (180 mg oral morphine / 5 = 36 mg hydromorphone, reduced 25-30% = ~25 mg/day, e.g., 4 mg PO q4h scheduled with 1-2 mg q2-4h prn).
Step 5 - Reassess at 24 hours for sedation, respiratory rate, and pain; titrate. If sedation persists at the reduced dose, cut further - persistence signals ongoing accumulation, not under-treatment.
3. Beyond the opioid change, what non-opioid and disease-directed measures do you add, and what safety netting does the family need?
Read the worked answer
Analgesic adjuvants and disease-directed therapy:
- Palliative radiotherapy to the dominant painful bone lesion(s) - single 8 Gy or 30 Gy in 10 fractions - is the highest-yield addition for metastatic bone pain and often allows opioid de-escalation.
- Continue denosumab with calcium/vitamin D and renal monitoring (his CrCl 26 and denosumab-related hypocalcemia risk both matter); confirm he is not also on a bisphosphonate.
- Reassess the prednisone 5 mg - if it is not required for an abiraterone or disease-specific reason, tapering may reduce delirium, hyperglycemia, and proximal myopathy. Do not stop abruptly if it has been chronic.
- Avoid NSAIDs entirely with CrCl 26. Avoid gabapentinoids at this creatinine unless there is a clear neuropathic component, and if used, dose for renal function (e.g., gabapentin 100 mg at bedtime) and accept the sedation risk.
- Continue a stimulant laxative regimen - opioids plus immobilization plus no NSAIDs equals high constipation risk; add an osmotic agent if no bowel movement in 48 hours.
Safety netting for the family: written instructions on when to call (unrousable, respiratory rate <8, new confusion), a take-home naloxone kit with teaching, fall and fracture precautions with PT/OT, and a single point of contact. Initiate advance care planning and hospice referral discussion now - goals of care should be aligned before the next crisis rather than during it.